NEW YORK (GenomeWeb News) – Biomagnetics Diagnostics said yesterday that it has acquired rights to intellectual property from Los Alamos National Laboratory related to biosensor and multiplex diagnostics technologies.
San Francisco-based Biomagnetics said that it plans to use the IP for the development of a handheld, integrated optical biosensor for highly accurate and rapid diagnosis of HIV/AIDS, malaria, tuberculosis, and other pathogens.
The IP acquisition follows a licensing deal that the firm inked with Los Alamos earlier this week, under which it gained access to optical biosensor technology developed at the lab. The new agreement covers IP for quantitative multiplex detection of pathogen biomarkers.
Biomagnetics has developed a high-throughput screening magnetic testing platform that provides qualitative and quantitative results from a single test, according to the firm's website. The platform detects viruses by measuring the magnetic field of micro-particles bonded to the virus "in a fraction of the time and costs of existing assays," it said.
Terms of the licenses were not disclosed.